MX2016012932A - Procedimientos novedosos para inducir una respuesta inmune. - Google Patents

Procedimientos novedosos para inducir una respuesta inmune.

Info

Publication number
MX2016012932A
MX2016012932A MX2016012932A MX2016012932A MX2016012932A MX 2016012932 A MX2016012932 A MX 2016012932A MX 2016012932 A MX2016012932 A MX 2016012932A MX 2016012932 A MX2016012932 A MX 2016012932A MX 2016012932 A MX2016012932 A MX 2016012932A
Authority
MX
Mexico
Prior art keywords
inducing
immune response
novel methods
methods
administrations
Prior art date
Application number
MX2016012932A
Other languages
English (en)
Spanish (es)
Inventor
Ripley Ballou William Jr
Ange Demoitie Marie-
Noelle Renelle DONNER Marie-
Ouaked Nadia
Theophile TEMMERMAN Stephane
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX2016012932A publication Critical patent/MX2016012932A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2016012932A 2014-04-02 2015-04-02 Procedimientos novedosos para inducir una respuesta inmune. MX2016012932A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1405921.6A GB201405921D0 (en) 2014-04-02 2014-04-02 Novel methods for inducing an immune response
PCT/EP2015/057423 WO2015150567A1 (en) 2014-04-02 2015-04-02 Novel methods for inducing an immune response

Publications (1)

Publication Number Publication Date
MX2016012932A true MX2016012932A (es) 2016-12-07

Family

ID=50737873

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016012932A MX2016012932A (es) 2014-04-02 2015-04-02 Procedimientos novedosos para inducir una respuesta inmune.
MX2016012982A MX2016012982A (es) 2014-04-02 2015-04-02 Procedimientos novedosos para inducir una respuesta inmunitaria.
MX2022013912A MX2022013912A (es) 2014-04-02 2016-09-30 Procedimientos novedosos para inducir una respuesta inmunitaria.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2016012982A MX2016012982A (es) 2014-04-02 2015-04-02 Procedimientos novedosos para inducir una respuesta inmunitaria.
MX2022013912A MX2022013912A (es) 2014-04-02 2016-09-30 Procedimientos novedosos para inducir una respuesta inmunitaria.

Country Status (18)

Country Link
US (3) US10688168B2 (enExample)
EP (2) EP3125930B1 (enExample)
JP (2) JP6655549B2 (enExample)
KR (2) KR20160132115A (enExample)
CN (2) CN106456739A (enExample)
AR (1) AR099960A1 (enExample)
AU (1) AU2015239025B2 (enExample)
BE (1) BE1022355B1 (enExample)
BR (2) BR112016022787A2 (enExample)
CA (2) CA2943007C (enExample)
EA (1) EA037405B1 (enExample)
ES (2) ES2961840T3 (enExample)
GB (1) GB201405921D0 (enExample)
IL (1) IL247493B (enExample)
MX (3) MX2016012932A (enExample)
SG (1) SG11201607086QA (enExample)
WO (2) WO2015150567A1 (enExample)
ZA (1) ZA201605955B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
FR3066920A1 (fr) 2017-05-30 2018-12-07 Glaxosmithkline Biologicals S.A. Nouveaux procedes de fabrication d'un adjuvant
WO2019106192A1 (en) 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Saponin purification
CA3142300C (en) 2019-06-05 2025-02-04 Glaxosmithkline Biologicals Sa SAPONIN PURIFICATION
CN113125756B (zh) * 2020-07-15 2022-10-25 南京岚煜生物科技有限公司 抗体标准品赋值和抗原中和当量确定的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US152200A (en) * 1874-06-16 Improvement in garters
US1002607A (en) * 1905-08-28 1911-09-05 John Willard Taylor Paper pulley.
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP1569515A4 (en) 2002-10-23 2006-04-26 Glaxosmithkline Biolog Sa MALARIA vaccine method
EA016648B1 (ru) 2004-10-14 2012-06-29 Круселл Холланд Б.В. Применение дефектного по репликации рекомбинантного аденовируса, содержащего гетерологичную нуклеиновую кислоту, кодирующую антиген cs возбудителя малярии, и белкового антигена, содержащего белок cs или его фрагмент, для лечения или профилактики малярии
PL2457926T3 (pl) * 2005-04-29 2015-03-31 Glaxosmithkline Biologicals Sa Nowy sposób profilaktyki lub leczenia zakażenia m. tuberculosis
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
EP2368568A1 (en) * 2006-11-01 2011-09-28 Immport Therapeutics, INC. Compositions and methods for immunodominant antigens
HUE031411T2 (en) * 2007-03-02 2017-07-28 Glaxosmithkline Biologicals Sa New Methods and Preparations
PE20090146A1 (es) * 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
WO2010010179A1 (en) * 2008-07-25 2010-01-28 Glaxosmithkline Biologicals S.A. The tuberculosis rv2386c protein, compositions and uses thereof
UA107330C2 (uk) * 2008-07-25 2014-12-25 Глаксосмітклайн Байолоджікалз С.А. Туберкульозний білок rv3616c та його застосування
EP2315597B1 (en) * 2008-07-25 2017-08-23 GlaxoSmithKline Biologicals S.A. Novel compositions and methods
PL2528621T3 (pl) * 2010-01-27 2017-07-31 Glaxosmithkline Biologicals S.A. Zmodyfikowane antygeny gruźlicy
HUE028452T2 (en) * 2010-12-14 2016-12-28 Glaxosmithkline Biologicals Sa Mycobacterium antigenic preparations
US20170056345A1 (en) * 2014-02-18 2017-03-02 Stc.Unm Booster drug therapy for mycobacterium infections
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
JP2017513860A (ja) * 2014-04-24 2017-06-01 スタテンス セールム インスティトゥート 新規結核菌（ｍ．ｔｕｂｅｒｃｕｌｏｓｉｓ）ワクチン
GB201513176D0 (en) * 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response

Also Published As

Publication number Publication date
BR112016022463A2 (pt) 2017-10-10
IL247493B (en) 2022-08-01
ES2853773T3 (es) 2021-09-17
EP3125929A1 (en) 2017-02-08
JP6645982B2 (ja) 2020-02-14
EP3125930A1 (en) 2017-02-08
BE1022355A1 (fr) 2016-02-16
BR112016022787A2 (pt) 2018-03-27
ES2961840T3 (es) 2024-03-14
JP6655549B2 (ja) 2020-02-26
BE1022355B1 (fr) 2016-03-26
EP3125930B1 (en) 2020-12-02
US11951161B2 (en) 2024-04-09
CA2943007C (en) 2024-01-09
CA2943007A1 (en) 2015-10-08
AU2015239025A1 (en) 2016-09-22
EA037405B1 (ru) 2021-03-25
KR20230075525A (ko) 2023-05-31
AR099960A1 (es) 2016-08-31
US10624961B2 (en) 2020-04-21
US20200306353A1 (en) 2020-10-01
CN106456739A (zh) 2017-02-22
US20170112914A1 (en) 2017-04-27
CN106456738A (zh) 2017-02-22
ZA201605955B (en) 2019-04-24
WO2015150567A1 (en) 2015-10-08
EA201691638A1 (ru) 2017-04-28
GB201405921D0 (en) 2014-05-14
KR20160132115A (ko) 2016-11-16
EP3125929C0 (en) 2023-11-01
IL247493A0 (en) 2016-11-30
SG11201607086QA (en) 2016-09-29
EP3125929B8 (en) 2023-12-27
JP2017511327A (ja) 2017-04-20
CA2943711A1 (en) 2015-10-08
EP3125929B1 (en) 2023-11-01
MX2016012982A (es) 2016-12-07
CN106456738B (zh) 2021-06-29
AU2015239025B2 (en) 2018-01-25
US10688168B2 (en) 2020-06-23
KR102762440B1 (ko) 2025-02-03
MX2022013912A (es) 2022-12-13
WO2015150568A1 (en) 2015-10-08
JP2017511324A (ja) 2017-04-20
US20170136110A1 (en) 2017-05-18

Similar Documents

Publication Publication Date Title
IL283058A (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
IL269830A (en) Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
HUE047784T2 (hu) Anti-TIM3 antitestek és alkalmazási eljárások
EA201692512A1 (ru) Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки
EP4070818A3 (en) Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
EP3134510A4 (en) Recombinant listeria vaccine strains and methods of producing the same
EP3200831A4 (en) Vaccines having an antigen and interleukin-21 as an adjuvant
EP3112378A4 (en) Wt1 antigenic polypeptide, and anti-tumor agent containing said polypeptide
EP3288538A4 (en) Methods for potentiating an immune response using depot-forming and non-depot-forming vaccines
MX2016012932A (es) Procedimientos novedosos para inducir una respuesta inmune.
EP3204414A4 (en) Novel anti-nodal antibodies and methods of using same
MX2017005975A (es) Anticuerpos anti factor de crecimiento derivado de plaquetas b (pdgf-b) y metodos de uso.
EP3107567A4 (en) Methods of modulating an immune response
EP3178491A4 (en) Composition for enhancing induction of humoral immunity, and vaccine pharmaceutical composition
EP3308800A4 (en) Adjuvant for vaccines, vaccine, and immunity induction method
EP3010340A4 (en) Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency
ZA201608487B (en) Dual adjuvant vaccine compositions, preparation and uses
DK3352783T3 (da) Vaccine omfattende immun-isolerede celler som producerer en immunmodulator
PL3402802T3 (pl) Kompozycje i sposoby generowania odpowiedzi immunologicznej względem antygenu powiązanego z guzem nowotworowym
EP3151858A4 (en) Antibody guided vaccines and methods of use for generation of rapid mature immune responses
EP3104887A4 (en) Vaccines with interleukin-17 as an adjuvant
ZA201608104B (en) Co-cultivation of propionibacterium and yeast
EP3097420A4 (en) Methods and compositions for immune dis-inhibition
EP3170068A4 (en) Using timing of character input to verify password
EP3197558A4 (en) Compositions and methods for transient immune response modulation during vaccination